AstraZeneca PLC (AZN)vsBasel Medical Group Ltd Ordinary Shares (BMGL)
AZN
AstraZeneca PLC
$173.30
-1.13%
HEALTHCARE · Cap: $261.94B
BMGL
Basel Medical Group Ltd Ordinary Shares
$5.95
-0.50%
HEALTHCARE · Cap: $8.80M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 410042% more annual revenue ($60.44B vs $14.74M). AZN leads profitability with a 17.2% profit margin vs -68.2%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
BMGL
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.7%
Fair Value
$193.96
Current Price
$173.30
$20.66 discount
Intrinsic value data unavailable for BMGL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.9%
Generating 2.1B in free cash flow
Revenue surging 67.1% year-over-year
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : BMGL
The strongest argument for BMGL centers on Revenue Growth, Price/Book. Revenue growth of 67.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : BMGL
The primary concerns for BMGL are EPS Growth, Market Cap, Debt/Equity. Debt-to-equity of 1.57 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while BMGL is a hypergrowth play — different risk/reward profiles.
BMGL is growing revenue faster at 67.1% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 38/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Basel Medical Group Ltd Ordinary Shares
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Basel Medical Group Ltd provides healthcare services. The company is headquartered in Singapore.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?